Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
暂无分享,去创建一个
Stephen W Dusza | Allan C Halpern | Klaus J Busam | A. Halpern | S. Dusza | K. Busam | C. Benvenuto-Andrade | P. Myskowski | Anna Liza C Agero | Cristiane Benvenuto-Andrade | Patricia Myskowski | A. Agero
[1] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] U. Rodeck,et al. The EGF receptor - an essential regulator of multiple epidermal functions. , 2000, European journal of dermatology : EJD.
[3] R. Dummer,et al. Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition. , 2003, Swiss medical weekly.
[4] E. Rowinsky. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. , 2004, Annual review of medicine.
[5] J. Baselga,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] David A. Smith,et al. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Perez-soler. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? , 2003, Oncology.
[8] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Ramalingam,et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] A. Stead,et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects , 2004, Investigational New Drugs.
[11] E. Cortesi,et al. Management of cutaneous adverse effects during treatment with ZD1839 in advanced non-small cell lung cancer (NSCLC): Surprising efficacy of early local treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Motonori Yamaguchi,et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. , 2003, Anticancer research.
[14] A. Halpern,et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.
[15] R. Motzer,et al. Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma , 2003, Investigational New Drugs.
[16] E. Vokes,et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Stead,et al. Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Crowley,et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Toms,et al. Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme , 2005 .
[20] C. Bokemeyer,et al. 53 A phase I study of epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC) , 2003 .
[21] A. Ullrich,et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. , 1995, The EMBO journal.
[22] R. Mayer,et al. 279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin , 2004 .
[23] Roy S Herbst,et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Koropatnick,et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] I. Kurokawa,et al. Purpuric drug eruption possibly due to gefinitib (Iressa®) , 2004, International journal of dermatology.
[26] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[27] G. Giaccone,et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor , 2002, The British journal of dermatology.
[28] A. Kimyai-Asadi,et al. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. , 2002, Archives of dermatology.
[29] K. Papadopoulos,et al. A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC) , 2005 .
[30] A. Tolcher,et al. Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule , 2004, Clinical Cancer Research.
[31] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Kris,et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Joon-Oh Park,et al. Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[34] M. Ychou,et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours , 2004, The British journal of dermatology.
[35] Geoffrey S Ginsburg,et al. Targeted therapies for cancer 2004. , 2004, American journal of clinical pathology.
[36] A. Halpern,et al. Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.
[37] B. Mirakhur,et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. , 2002, Journal of the American Academy of Dermatology.
[38] Alain Spatz,et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.
[39] M. Hidalgo,et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] F. Lund-Johansen,et al. Epidermal Growth Factor Receptor Inhibition Induces Trichomegaly , 2003, Acta oncologica.
[41] J. Baselga,et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Kris,et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Mita,et al. Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. , 2004, Journal of Clinical Oncology.
[46] L. Saltz,et al. The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances , 2003 .
[47] R. Herbst,et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. , 2003, Clinical lung cancer.
[48] E K Rowinsky,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.